[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561563":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":72,"collaborators":28,"id":74,"slug":28,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":28,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":28,"studyType":86,"phases":87,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":38,"whyStopped":28,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"AAVantgarde Bio Srl","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","AAVB-081 dose level 1",[13],"Biological: AAVB-081",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","AAVB-081 dose level 2",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","AAVB-081 dose level 3",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","AAVB-081","Single subretinal administration",[9,15,19],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Clinical Operations Manager","CONTACT","+448000465680","clinicaltrials@aavantgarde.com",[36,51,64],{"facility":37,"status":38,"city":39,"state":28,"zip":28,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"University of Campania Luigi Vanvitelli","RECRUITING","Naples","Italy","IT",{"type":43,"coordinates":44},"Point",[45,46],14.26811,40.85216,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":28,"phoneExt":28,"email":28},"Francesca Simonelli",{"facility":52,"status":38,"city":53,"state":28,"zip":28,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Moorfields Eye Hospital","London","United Kingdom","UK",{"type":43,"coordinates":57},[58,59],-0.12574,51.50853,{"lat":59,"lon":58},[62],{"name":63,"role":32,"phone":28,"phoneExt":28,"email":28},"Michel Michaelides",{"facility":65,"status":38,"city":53,"state":28,"zip":28,"country":54,"countryCode":55,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Retina Clinic London",{"type":43,"coordinates":67},[58,59],{"lat":59,"lon":58},[70],{"name":71,"role":32,"phone":28,"phoneExt":28,"email":28},"Paulo E Stanga",{"type":73,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100561563",false,"NCT06591793","Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","A Phase 1\u002F2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","Inclusion Criteria:\n\n* Molecular diagnosis of USB1B due to MYO7A mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with an Investigation Product in the past 6 months\n* Previous participation in another Gene Therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","18 Years","50 Years",{"count":84,"type":85},15,"ESTIMATED","INTERVENTIONAL",[88,89],"PHASE1","PHASE2","The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.",[92],"Usher Syndrome, Type 1B",[94,95,96,97],"Usher Syndrome","MYO7A","USH1B","Retinitis Pigmentosa","2025-05-01",{"date":100,"type":101},"2025-05-02","ACTUAL",{"date":103,"type":101},"2024-07-02",{"date":105,"type":85},"2029-07",{"name":5,"class":6},3]